Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models

Nationwide Routine Childhood Vaccination Coverage During the COVID-19 Pandemic in Jordan: Current Situation, Reasons, and Predictors of Vaccination

(2022) Eman Y. Abu-rish et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival

(2022) Matteo Santoni et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Statins and prostate cancer—hype or hope? The epidemiological perspective

(2022) Emma L. Craig et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Atorvastatin is associated with reduced cisplatin-induced hearing loss

(2021) Katharine A. Fernandez et al.   JOURNAL OF CLINICAL INVESTIGATION

Association of statin use with clinical outcomes in patients with triple‐negative breast cancer

(2021) Malgorzata K. Nowakowska et al.   CANCER

Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors

(2021) Shirley Tenesaca et al.   Journal for ImmunoTherapy of Cancer

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer

(2021) Gi-Hoon Nam et al.   Journal for ImmunoTherapy of Cancer

Pitavastatin Is a Highly Potent Inhibitor of T-Cell Proliferation

(2021) Linda Voss et al.   Pharmaceuticals

Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Statins) Suppress Proliferation and Motility of Human CD4+ T Lymphocytes in Culture

(2021) N. V. Radyukhina et al.   BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE

Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma

(2021) Minsu Kwon et al.   CANCER LETTERS

Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers

(2021) Anne Michelli Reis Silveira et al.   Frontiers in Pharmacology

Targeting the Tumor Microenvironment: A Literature Review of the Novel Anti-Tumor Mechanism of Statins

(2021) Peng-Fei Zhu et al.   Frontiers in Oncology

Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects

(2020) Zhihua Jiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer

(2020) Wenda Ye et al.   OncoImmunology

Lovastatin protects against cisplatin-induced hearing loss in mice

(2020) Katharine Fernandez et al.   HEARING RESEARCH

Statins as anti-cancer agents in the era of precision medicine

(2020) Joseph Longo et al.   CLINICAL CANCER RESEARCH

Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors

(2020) Patricia M.R. Pereira et al.   CLINICAL CANCER RESEARCH

Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy

(2020) Zachary S Buchwald et al.   Journal for ImmunoTherapy of Cancer

High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients

(2020) Luca Cantini et al.   EUROPEAN JOURNAL OF CANCER

Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer

(2019) Abhinav Gupta et al.   ORAL ONCOLOGY

Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients with Head and Neck Cancer: Results of the Biology-Driven Phase Ii Clinical Trial Pravacur

(2019) Celine Bourgier et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment

(2019) Xingzhe Ma et al.   Cell Metabolism

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer

(2019) So-Jin Park et al.   ORAL ONCOLOGY

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

Cholesterol negatively regulates IL-9–producing CD8+T cell differentiation and antitumor activity

(2018) Xingzhe Ma et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer

(2018) Roy Xiao et al.   OncoImmunology

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms

(2018) Ellen C. Moore et al.   OncoImmunology

The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery

(2018) Yun Xia et al.   CELL

Retinal Cholesterol Content is Reduced in Simvastatin-Treated Mice Due to Inhibited Local Biosynthesis Albeit Increased Uptake of Serum Cholesterol

(2018) Natalia Mast et al.   DRUG METABOLISM AND DISPOSITION

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function

(2018) Paul E. Clavijo et al.   Cancer Immunology Research

Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling

(2017) Isobel Okoye et al.   Oncotarget

Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells

(2017) Paul E. Clavijo et al.   Oncotarget

Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma

(2017) Linda Tran et al.   Cancer Immunology Research

Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism

(2016) Wei Yang et al.   NATURE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers

(2016) E. C. Moore et al.   Cancer Immunology Research

Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

(2016) E. Moore et al.   Cancer Immunology Research

mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer

(2015) Harrison Cash et al.   Oncotarget

What is a relevant statin concentration in cell experiments claiming pleiotropic effects?

(2011) Linda Björkhem-Bergman et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Simvastatin in Apolipoprotein E Deficient Mice With Surgically Induced Chronic Renal Failure

(2008) Ognen Ivanovski et al.   JOURNAL OF UROLOGY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE